Compare UAN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | MGTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2008 | 2018 |
| Metric | UAN | MGTX |
|---|---|---|
| Price | $127.50 | $11.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 18.8K | ★ 688.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | 33.02 |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | 15.36 | ★ 144.57 |
| 52 Week Low | $86.43 | $6.62 |
| 52 Week High | $139.50 | $15.35 |
| Indicator | UAN | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 47.40 |
| Support Level | $121.55 | $8.84 |
| Resistance Level | $139.42 | $11.85 |
| Average True Range (ATR) | 2.80 | 0.59 |
| MACD | 0.91 | -0.19 |
| Stochastic Oscillator | 83.90 | 28.08 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.